Biocon - Disclosures to Stock Exchange

Quick links

> INVESTORS

	Overview

	Corporate Structure

	Corporate Governance

	Company History

	Annual General Meeting

	Postal Ballot

	Investor FAQs

	Stock Info

	Financial Results

	Subsidiary Financials

	Annual Report

	Disclosure to Stock Exchange

	Nomination form

	Press Releases

	Presentations

	Analyst Coverage

	Investor Contacts

Disclosure to Stock Exchange

December 2017

29 Dec

Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs

22 Dec

Intimation of Board Meeting

21 Dec

Intimation Regarding Analysts / Institutional Investors Meet

20 Dec

Intimation Regarding Analysts / Institutional Investors Meet

19 Dec

Intimation Regarding Analysts / Institutional Investors Meet

15 Dec

Intimation Regarding Analysts / Institutional Investors Meet

14 Dec

Intimation Regarding Analysts / Institutional Investors Meet

13 Dec

Biocon’s Clarification post media reports on “Biocon on the FDA list for not paying facility fee”

07 Dec

Intimation Regarding Analysts / Institutional Investors Meet

07 Dec

Results of Postal Ballot / eVoting

07 Dec

Intimation Regarding Analysts / Institutional Investors Meet

05 Dec

Intimation Regarding Analysts / Institutional Investors Meet

01 Dec

U.S. FDA Approves Mylan and Biocon´s Ogivri^TM the First Biosimilar for Trastuzumab, for the Treatment of HER2Positive Breast and Gastric Cancers

01 Dec

European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim

November 2017

23 Nov

Intimation Regarding Analysts / Institutional Investors Meet

23 Nov

Biocon Launches KRABEVA^® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India

20 Nov

Biocon's Facility Receives EIR with VAI status, Inspection Closed

15 Nov

Intimation Regarding Analysts / Institutional Investors Meet

14 Nov

Intimation Regarding Analysts / Institutional Investors Meet

10 Nov

Intimation Regarding Analysts / Institutional Investors Meet

08 Nov

Presentation on financial results of the Company for the quarter and half year ended September 30, 2017

06 Nov

Resubmission of Biosimilar Trastuzumab and Pegfilgrastim Dossiers with EMA

06 Nov

Postal Ballot Advertisement

03 Nov

Postal Ballot Notice to Shareholders

October 2017

30 Oct

Intimation Regarding Analysts / Institutional Investors Meet

27 Oct

Intimation Regarding Analysts / Institutional Investors Meet

25 Oct

Biocon Ranked Among Top 10 Global Pharma & Biotech Employers

10 Oct

US FDA Issues Complete Response Letter for Proposed Biosimilar Pegfilgrastim

September 2017

27 Sept

Intimation of Board Meeting

21 Sept

Intimation Regarding Analysts / Institutional Investors Meet

19 Sept

Intimation Regarding Analysts / Institutional Investors Meet

18 Sept

Biocon’s Facility in Vishakhapatnam completes US FDA Inspection with no observations

15 Sept

Intimation Regarding Analysts / Institutional Investors Meet

8 Sept

Intimation Regarding Analysts / Institutional Investors Meet

7 Sept

Biocon´s Insulins facility in Malaysia Receives EU GMP Compliance Certificate

6 Sept

JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment

5 Sept

Intimation Regarding Analysts / Institutional Investors Meet

August 2017

30 Aug

USFDA Target Action Date for Trastuzumab Reset to December 3, 2017

29 Aug

Intimation Regarding Analysts / Institutional Investors Meet

23 Aug

Intimation Regarding Analysts / Institutional Investors Meet

22 Aug

Intimation Regarding Analysts / Institutional Investors Meet

17 Aug

Intimation Regarding Analysts / Institutional Investors Meet

16 Aug

Company Statement on Status of EMA Dossiers

11 Aug

Incorporation of WOS

07 Aug

Intimation Regarding Analysts / Institutional Investors Meet

July 2017

31 Jul

Company Statement on USFDA Visit in May/June2017. CAPA is under Implementation

31 Jul

Intimation Regarding Analysts / Institutional Investors Meet

14 Jul

Press Release titled "FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab"

09 Jul

Company's Statement on the outcome of pre-approval inspection audits by French health agency, L'Agence nationale de securite du medicament et des produits de sante (ANSM) on behalf of European Medicines Agency (EMA)

June 2017

23 Jun

Intimation Regarding Analysts / Institutional Investors Meet

20 Jun

Intimation Regarding Analysts / Institutional Investors Meet

11 Jun

Press Release titled "Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions"

1 Jun

Intimation Regarding Analysts / Institutional Investors Meet

May 2017

11 May

Intimation Regarding Analysts / Institutional Investors Meet

10 May

Biocon Statement in response to Media Reports on USFDA Form 483s for Biocon Limited.

08 May

Newspaper Advertisement For Dispatch Of Postal Ballot Notice And Postal Ballot Form.

05 May

Notice Of Postal Ballot

April 2017

28 Apr

Intimation regarding Analyst / Institutional Investor Meet

28 Apr

Presentation - Analysts/Institutional Investors Meet

27 Apr

Outcome of Board Meeting

March 2017

30 Mar

Intimation regarding Analyst / Institutional Investor Meet

27 Mar

Intimation regarding Analyst / Institutional Investor Meet

15 Mar

Intimation regarding Analyst / Institutional Investor Meet

06 Mar

Intimation regarding Analyst / Institutional Investor Meet

03 Mar

Biocon's statement in response to Delhi High Court Interim Order

02 Mar

Intimation regarding Analyst / Institutional Investor Meet

February 2017

27 Feb

Intimation regarding Analyst / Institutional Investor Meet

24 Feb

Intimation regarding Analyst / Institutional Investor Meet

22 Feb

Intimation regarding Analyst / Institutional Investor Meet

16 Feb

USFDA accepts Biologics License Application (BLA) for Mylan and Biocon's proposed Biosimilar Pegfilgrastim for Review

14 Feb

Intimation regarding Analyst / Institutional Investor Meet

07 Feb

Intimation regarding Analyst / Institutional Investor Meet

January 2017

30 Jan

Intimation regarding Analyst / Institutional Investor Meet

24 Jan

Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore; Revenue Rises 32% at Rs 1092 Crore; EBITDA Increases 57% to Rs 324 Crore

11 Jan

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab

January to July 2020
January to December 2019
January to December 2018
January to December 2017
January to December 2016
December 2015


Biocon	Businesses	Recommended sites		Biocon on
Home About Us Investor Relations Media Relations Careers Site Map Contact Us	Our Growth Accelerators Fact Sheet Branded Formulations Biopharmaceuticals Research Services Active Discovery Program	ABLE Karnataka Vision Group on BT Syngene International Biocon Academy

Report adverse event/side effects and product complaints

* Disclaimer			© 2018, Biocon. All Rights Reserved